Zoldonrasib and KRAS G12D: What a New Pancreatic Cancer Study Means for Appendix Cancer Research

Researchers are testing zoldonrasib, a new targeted drug designed to block the KRAS G12D mutation – a genetic change that helps drive the growth of many pancreatic cancers. Early results, presented at the 2026 ESMO Gastrointestinal Cancers Congress, are encouraging.

What the study found

In an early-stage study of 81 people with previously untreated metastatic pancreatic cancer carrying the KRAS G12D mutation, zoldonrasib combined with standard chemotherapy:

• led to significant tumor shrinkage in many patients
• reduced signs of cancer in the blood (circulating tumor DNA)
• did not cause unexpected safety problems beyond typical chemotherapy side effects

The results are encouraging, but this was a small, early study. A larger Phase III trial is now underway to determine whether the treatment truly improves outcomes for patients.

Why it matters for appendix cancer

Although this study focused on pancreatic cancer, it has potential relevance to appendix cancer. KRAS mutations are common in appendix cancer, especially the mucinous subtypes, and the new generation of KRAS-directed drugs may have relevance for these cancers. Zoldonrasib is not approved for appendix cancer, and research into KRAS-targeted treatments for appendix cancer is still evolving – but it is moving quickly.

Patients may wish to ask their care team whether tumor genomic sequencing has been done and whether their cancer carries a KRAS mutation. Keep an eye on ACPMP’s Clinical Trials Database for new studies.

Learn more

Read The ASCO Post’s coverage of the study.

This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.